---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-031632"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2022-12-09T23:59:59+00:00"
generated_at: "2026-06-21T06:45:36.639385+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# X4 Pharmaceuticals prices $65M public offering of common stock and warrants

## Summary
- Offering includes 52.3M shares and 6.8M pre-funded warrants at $1.10/share.
- Class C warrants to purchase 29.55M shares at $1.50/share, expiring Dec 2027.
- Gross proceeds $65M; net proceeds ~$59.8M after discounts and expenses.
- Underwriters granted 30-day option for up to 8.865M additional shares.
- Closing expected Dec 9, 2022; Piper Sandler, Stifel, Cantor as joint bookrunners.

## SEC filing metadata
- accession: 0001628280-22-031632
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2022-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828022031632/0001628280-22-031632-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828022031632/xfor-20221206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-031632
- JSON: https://secwatch.observer/filing/0001628280-22-031632.json
- Plain text: https://secwatch.observer/filing/0001628280-22-031632.txt

## Key facts
- Material Agreements
  X4 Pharmaceuticals, Inc entered into Underwriting Agreement with Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co., as representatives of the several underwriters valued at approximately $59.8 million (effective 2022-12-07).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co., as representatives of the several underwriters
  - Value: approximately $59.8 million
  - Effective: 2022-12-07
  source text: On December 7, 2022, X4 Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 52,300,000 shares of the Company’s common stock, pre-funded warrants to purchase 6,800,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) and Class C warrants to purchase 29,550,000 shares of the Company’s common stock or Pre-Funded Warrants (the “Class C Warrants”) at a price to the public of $1.10 per share for common stock and accompanying Class C Warrant and $1.099 per Pre-Funded Warrant and accompanying Class C Warrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828022031632/0001628280-22-031632-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.